GD2-targeting therapy is a promising approach in cancer immunotherapy, targeting the disialoganglioside GD2, a surface antigen expressed in various neuroectodermal and epithelial tumors. GD2 plays a role in tumor growth, invasion, and metastasis, and its high expression is associated with a malignant phenotype. GD2 is a glycosphingolipid that is stably expressed on tumor cells, making it a suitable target for antibodies or chimeric antigen receptors (CARs). Various approaches have been developed, including monoclonal antibodies (mAbs), vaccines, photoimmunotherapy, and cell therapy. mAbs such as dinutuximab, naxitamab, and hu14.18K322A have been used in clinical trials, but they face challenges such as immunogenicity and side effects. Chimeric and humanized mAbs have been developed to reduce these issues. CAR-based therapies are also being explored, with efforts to optimize CARs by modifying their design or using different cell types. GD2 aptamers are being used for targeting, and cell therapy involves the use of allogeneic immunocompetent cells to enhance GD2 therapy. Immunotherapy can combine diagnostic and therapeutic methods, allowing for early detection of disease and minimal residual disease. The review discusses various immunotherapy methods, their advantages and disadvantages, and highlights future directions for GD2 therapy. Key strategies include improving mAb design, combining with other drugs, and exploring new delivery methods. GD2-targeting therapy holds promise for the treatment of neuroblastoma and other cancers.GD2-targeting therapy is a promising approach in cancer immunotherapy, targeting the disialoganglioside GD2, a surface antigen expressed in various neuroectodermal and epithelial tumors. GD2 plays a role in tumor growth, invasion, and metastasis, and its high expression is associated with a malignant phenotype. GD2 is a glycosphingolipid that is stably expressed on tumor cells, making it a suitable target for antibodies or chimeric antigen receptors (CARs). Various approaches have been developed, including monoclonal antibodies (mAbs), vaccines, photoimmunotherapy, and cell therapy. mAbs such as dinutuximab, naxitamab, and hu14.18K322A have been used in clinical trials, but they face challenges such as immunogenicity and side effects. Chimeric and humanized mAbs have been developed to reduce these issues. CAR-based therapies are also being explored, with efforts to optimize CARs by modifying their design or using different cell types. GD2 aptamers are being used for targeting, and cell therapy involves the use of allogeneic immunocompetent cells to enhance GD2 therapy. Immunotherapy can combine diagnostic and therapeutic methods, allowing for early detection of disease and minimal residual disease. The review discusses various immunotherapy methods, their advantages and disadvantages, and highlights future directions for GD2 therapy. Key strategies include improving mAb design, combining with other drugs, and exploring new delivery methods. GD2-targeting therapy holds promise for the treatment of neuroblastoma and other cancers.